Foghorn Therapeuticsinc Stock Today

FHTX Stock  USD 6.28  0.21  3.46%   

Performance

3 of 100

 
Low
 
High
Insignificant

Odds Of Distress

Less than 50

 
100  
 
Zero
About Average
Foghorn TherapeuticsInc is trading at 6.28 as of the 28th of March 2024; that is 3.46% increase since the beginning of the trading day. The stock's open price was 6.07. Foghorn TherapeuticsInc has 50 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Foghorn TherapeuticsInc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of February 2024 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
23rd of October 2020
Category
Healthcare
Classification
Health Care
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. The company has 42.57 M outstanding shares of which 1.25 M shares are currently shorted by private and institutional investors with about 4.57 trading days to cover. More on Foghorn TherapeuticsInc

Moving against Foghorn Stock

  0.63VBIV VBI Vaccines Financial Report 20th of May 2024 PairCorr
  0.45TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr

Foghorn Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Foghorn TherapeuticsInc's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Foghorn TherapeuticsInc or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO PresidentAdrian Gottschalk
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Foghorn TherapeuticsInc report their recommendations after researching Foghorn TherapeuticsInc's financial statements, talking to executives and customers, or listening in on Foghorn TherapeuticsInc's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Foghorn TherapeuticsInc. The Foghorn consensus assessment is calculated by taking the average forecast from all of the analysts covering Foghorn TherapeuticsInc.
Financial Strength
Based on the measurements of operating efficiency obtained from Foghorn TherapeuticsInc's historical financial statements, Foghorn TherapeuticsInc may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Foghorn TherapeuticsInc is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.130.1195
Significantly Up
Slightly volatile
Total Current Liabilities87.8 M58.4 M
Way Up
Slightly volatile
Non Current Liabilities Total185.9 M304.7 M
Way Down
Slightly volatile
Total Assets280.8 M285.9 M
Fairly Down
Slightly volatile
Total Current Assets237.1 M240.2 M
Fairly Down
Slightly volatile
Foghorn TherapeuticsInc's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Foghorn TherapeuticsInc's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Foghorn TherapeuticsInc's financial leverage. It provides some insight into what part of Foghorn TherapeuticsInc's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Foghorn TherapeuticsInc's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Foghorn TherapeuticsInc deploys its capital and how much of that capital is borrowed.
Liquidity
Foghorn TherapeuticsInc cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 45.07 M in liabilities with Debt to Equity (D/E) ratio of 2.19, implying the company greatly relies on financing operations through barrowing. Foghorn TherapeuticsInc has a current ratio of 6.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Foghorn TherapeuticsInc until it has trouble settling it off, either with new capital or with free cash flow. So, Foghorn TherapeuticsInc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Foghorn TherapeuticsInc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Foghorn to invest in growth at high rates of return. When we think about Foghorn TherapeuticsInc's use of debt, we should always consider it together with cash and equity.

Other Non Cash Items

(1.71 Million)
Foghorn TherapeuticsInc (FHTX) is traded on NASDAQ Exchange in USA. It is located in 500 Technology Square, Cambridge, MA, United States, 02139 and employs 116 people. Foghorn TherapeuticsInc is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 259.86 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Foghorn TherapeuticsInc's market, we take the total number of its shares issued and multiply it by Foghorn TherapeuticsInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Foghorn TherapeuticsInc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 42.57 M outstanding shares of which 1.25 M shares are currently shorted by private and institutional investors with about 4.57 trading days to cover. Foghorn TherapeuticsInc currently holds about 373.5 M in cash with (118.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Foghorn TherapeuticsInc Probability Of Bankruptcy
Ownership Allocation
Foghorn TherapeuticsInc holds a total of 42.57 Million outstanding shares. Over half of Foghorn TherapeuticsInc's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Foghorn TherapeuticsInc. Please watch out for any change in the institutional holdings of Foghorn TherapeuticsInc as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Foghorn Ownership Details

Foghorn Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Foghorn TherapeuticsInc jumping above the current price in 90 days from now is about 31.99%. The Foghorn TherapeuticsInc probability density function shows the probability of Foghorn TherapeuticsInc stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.5973. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Foghorn TherapeuticsInc will likely underperform. Additionally, foghorn TherapeuticsInc has an alpha of 0.2696, implying that it can generate a 0.27 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 6.28HorizonTargetOdds Above 6.28
67.93%90 days
 6.28 
31.99%
Based on a normal probability distribution, the odds of Foghorn TherapeuticsInc to move above the current price in 90 days from now is about 31.99 (This Foghorn TherapeuticsInc probability density function shows the probability of Foghorn Stock to fall within a particular range of prices over 90 days) .

Foghorn Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Foghorn TherapeuticsInc that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Foghorn TherapeuticsInc's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Foghorn TherapeuticsInc's value.
InstituionRecorded OnShares
Driehaus Capital Management Llc2023-12-31
343.7 K
Birchview Capital, Lp2023-12-31
320.9 K
Point72 Asset Management, L.p.2023-09-30
284.9 K
Northern Trust Corp2023-12-31
199.3 K
Sio Capital Management, Llc2023-12-31
121.7 K
Morgan Stanley - Brokerage Accounts2023-12-31
105.1 K
Panagora Asset Management Inc2023-12-31
97 K
Bank Of New York Mellon Corp2023-12-31
57.2 K
Charles Schwab Investment Management Inc2023-12-31
55.4 K
Flagship Ventures Management, Inc.2023-09-30
12.7 M
Fmr Inc2023-12-31
2.8 M
View Foghorn TherapeuticsInc Diagnostics

Foghorn TherapeuticsInc Historical Income Statement

Foghorn TherapeuticsInc Income Statement is one of the three primary financial statements used for reporting Foghorn's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Foghorn TherapeuticsInc revenue and expense. Foghorn TherapeuticsInc Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Foghorn TherapeuticsInc's Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 11.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 19.7 M in 2024. View More Fundamentals

Foghorn Stock Against Markets

Picking the right benchmark for Foghorn TherapeuticsInc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Foghorn TherapeuticsInc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Foghorn TherapeuticsInc is critical whether you are bullish or bearish towards Foghorn TherapeuticsInc at a given time. Please also check how Foghorn TherapeuticsInc's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Foghorn TherapeuticsInc without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run FinTech Suite Now

   

FinTech Suite

Use AI to screen and filter profitable investment opportunities
All  Next Launch Module

Foghorn TherapeuticsInc Corporate Management

Elected by the shareholders, the Foghorn TherapeuticsInc's board of directors comprises two types of representatives: Foghorn TherapeuticsInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Foghorn. The board's role is to monitor Foghorn TherapeuticsInc's management team and ensure that shareholders' interests are well served. Foghorn TherapeuticsInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Foghorn TherapeuticsInc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Karin HellsvikCorporate VPProfile
Saurabh SewakVice DevelopmentProfile
Allan MDChief OfficerProfile
Alfonso MDChief OfficerProfile
Gerald MdFounder BoardProfile

How to buy Foghorn Stock?

Before investing in Foghorn TherapeuticsInc, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Foghorn TherapeuticsInc. To buy Foghorn TherapeuticsInc stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Foghorn TherapeuticsInc. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Foghorn TherapeuticsInc stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Foghorn TherapeuticsInc stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Foghorn TherapeuticsInc stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Foghorn TherapeuticsInc, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn TherapeuticsInc guide.

Already Invested in Foghorn TherapeuticsInc?

The danger of trading Foghorn TherapeuticsInc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Foghorn TherapeuticsInc is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Foghorn TherapeuticsInc. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Foghorn TherapeuticsInc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Foghorn TherapeuticsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Foghorn TherapeuticsInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Foghorn Therapeuticsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Foghorn Therapeuticsinc Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn TherapeuticsInc guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Foghorn Stock analysis

When running Foghorn TherapeuticsInc's price analysis, check to measure Foghorn TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn TherapeuticsInc is operating at the current time. Most of Foghorn TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Foghorn TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn TherapeuticsInc's price. Additionally, you may evaluate how the addition of Foghorn TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is Foghorn TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Foghorn TherapeuticsInc. If investors know Foghorn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Foghorn TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.34)
Revenue Per Share
0.814
Quarterly Revenue Growth
0.379
Return On Assets
(0.20)
Return On Equity
(4.70)
The market value of Foghorn TherapeuticsInc is measured differently than its book value, which is the value of Foghorn that is recorded on the company's balance sheet. Investors also form their own opinion of Foghorn TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Foghorn TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Foghorn TherapeuticsInc's market value can be influenced by many factors that don't directly affect Foghorn TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Foghorn TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Foghorn TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Foghorn TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.